Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Hepatic Portal System01:21

Hepatic Portal System

5.1K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

508
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
508
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?

Gut·2020
Same author

Syphilitic hepatitis: Case report of an overlooked condition.

Clinical case reports·2020
Same author

Esophagogastroduodenoscopy: how far should we go? A point of view.

Revista espanola de enfermedades digestivas·2020
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

13.0K

急性肝脏孔水症是什么

Inês Marques1, Pedro Marcos2,3

  • 1Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.

Porto biomedical journal
|November 25, 2025
PubMed
概括

急性肝脏 (AHP) 是一种罕见的遗传性疾病,导致衰弱的神经瘤发作. 早期诊断和管理对于预防慢性并发症和改善患者结果至关重要.

科学领域:

  • 生物化学 生物化学
  • 遗传学 遗传学 是一个
  • 内部医学 内部医学

背景情况:

  • 毛孔病是一种罕见的遗传疾病,源于血生物合成酶的突变.
  • 这些突变导致有毒氨酸前体的积累,导致各种症状.
  • 本综述侧重于急性肝脏 (AHP),这是这些疾病的一个子集.

研究的目的:

  • 审查目前对急性肝脏孔水症 (AHP) 的理解.
  • 突出AHP的诊断方法和治疗策略.
  • 强调识别AHP和管理其慢性并发症的重要性.

主要方法:

  • 通过PubMed.使用MEDLINE进行了全面的文献审查.
  • 系统审查,临床试验,队列研究,病例控制研究,专家评价和指导方针是优先考虑的.
  • 分析的重点是了解AHP的呈现,诊断和管理.

主要成果:

  • 有四种类型的AHP存在:急性间歇性形性形症,多种形性形症,遗传性形性形症和δ-氨基烯酸脱水酶缺乏性形症.
  • 典型情况下,AHP呈现为带有严重腹部疼痛,神经精神症状或皮肤病变的神经瘤发作,主要影响15-50岁的女性.
  • 诊断包括生物化学测试 (ALA,PBG,氨酸) 和基因测试以确定定型;治疗包括高葡萄糖饮食,血红素,吉沃西兰和肝移植作为治疗方法.
关键词:
急性肝脏孔水症是什么这里是他的家园.这里是hemin hemin.肝脏 肝脏 肝脏 肝脏 肝脏 肝脏波菲里亚斯病毒是什么?

更多相关视频

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K

相关实验视频

Last Updated: Jan 10, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

13.0K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K
  • 慢性并发症如肝细胞癌,病和高血压需要监测.
  • 结论:

    • 由于AHP仍未得到充分的认可,因此需要在患有无法解释的腹痛,神经病变,精神症状或皮肤病变的患者中考虑.
    • 需要改进的诊断技术和新的治疗选择,以有效管理AHP.
    • 及时诊断和全面管理对于减轻AHP及其相关慢性健康问题的影响至关重要.